What is NextCure?
NextCure operates at the intersection of biotechnology and immunology, focusing on the discovery and development of innovative therapeutic candidates designed to address cancer and various immune-related pathologies. The company distinguishes itself through a specialized approach to immunomedicine, aiming to unlock new pathways for patient treatment where traditional therapies have historically faced limitations. By leveraging a deep understanding of immune system modulation, NextCure has established a significant footprint in the biopharmaceutical market, attracting high-caliber institutional partners who prioritize long-term scientific value and clinical efficacy.
How much funding has NextCure raised?
NextCure has raised a total of $324.8M across 4 funding rounds:
Series A
$67M
Stock Offering
$86.3M
Stock Offering
$150M
Other Financing Round
$21.5M
Series A (2016): $67M with participation from Canaan Partners, Pfizer Inc., OrbiMed, Alexandria Venture Investments, Lilly Asia Ventures, and Sofinnova Ventures
Stock Issuance/Offering (2019): $86.3M, investors not publicly disclosed
Stock Issuance/Offering (2019): $150M, investors not publicly disclosed
Other Financing Round (2025): $21.5M featuring Squadron Capital Management, Ikarian Capital, and Exome Asset Management
Key Investors in NextCure
Squadron Capital Management
Squadron Capital Management is an investment firm that provides strategic capital to companies, often focusing on growth-oriented opportunities within the healthcare and technology sectors.
Ikarian Capital
Ikarian Capital is a specialized investment firm that focuses on the life sciences industry, providing financial backing to companies developing breakthrough medical technologies and therapeutics.
Exome Asset Management
Exome Asset Management is an investment firm that targets high-growth opportunities in the healthcare and biotechnology markets, supporting companies through various stages of clinical development.
What's next for NextCure?
With the recent strategic investment, NextCure is poised to accelerate its clinical development programs, focusing on the maturation of its lead assets. The company's strategic roadmap emphasizes the transition from early-stage discovery to advanced clinical trials, a phase that requires significant capital allocation and operational precision. Moving forward, the firm will likely prioritize data readouts and potential collaborative partnerships to validate its therapeutic platform. As the company scales, the focus will remain on achieving key clinical milestones that demonstrate the safety and efficacy of its immunomedicine portfolio, ultimately aiming to deliver transformative outcomes for patients suffering from complex immune-related diseases.
See full NextCure company page
